Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $57.15 which represents a slight increase of $6.58 or 13.01% from the prior close of $50.57. The stock opened ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Halozyme (HALO – Research Report), with a ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...

JMP Securities analyst Jason Butler has reiterated their bullish stance on HALO stock, giving a Buy rating yesterday. Jason Butler has given ...

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98. Investors in Halozyme Therapeutics ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...

Shares of Halozyme Therapeutics rose after the company reported earnings growth in the latest quarter and raised its outlook for the year. The stock was up 11% to $56.25 in post-market trading.